Loading clinical trials...
Loading clinical trials...
This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
NCT07299695 · Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT07466420 · Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), and more
NCT06241560 · Idiopathic Pulmonary Fibrosis
NCT05674994 · Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions